LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist: a first-in-human, phase 1, randomised, placebo-controlled trial

Key finding

Method / model

Relevance

Coskun, T., et al. (2022). LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist: a first-in-human, phase 1, randomised, placebo-controlled trial. The Lancet Diabetes & Endocrinology, 10(10), 746-755.